Ann: ePAT Pain Assessment App Secures Regulatory Clearance, page-155

it was a stated milestone to get regulatory approval however i thought the Nviso agreement details would come first so i found it a welcome surprise in that regard. Which now leaves the Nviso agreement next , it will be interesting though the content of the agreement they have with Nviso. I think a strong partnership is another tick for institutions who always consider the company risk factors prior to investing their money into a company. Instos like retail aim to buy to profit however they go about the reasons as to WHY they buy very differently from the retail mum and dad. They also have far deeper pockets when it comes to taking a position so they will like the increased liquidity.

From my discussions yesterday with management it came about 6 weeks ahead of schedule i.e. in the front end of Q3, what this means about the next set of milestones timing i dont know, ideally fast track that forward but they were sticking to commercialisation which to them is SALES and not some other definition in Q4 which is anything between Oct to Dec-17, not too far away.

The mention of the peer review journal article is also big , to have the industry medical peers sign off EPT work and endorse it is a big kudos to the product, and will assist not only in achieving FDA approval in 2018 but also any type of "digital" standard a government body might want to place on the Epat app as the gold standard of objectively measuring pain assessment in cognitively impaired adults. Who is a bureaucratic to argue with the medical industry experts as evidenced by the peer review paper.

The next four months is going to see a lot happen.......